|Bid||4.03 x 400|
|Ask||4.05 x 400|
|Day's Range||4.02 - 4.09|
|52 Week Range||2.89 - 7.73|
|PE Ratio (TTM)||-2.08|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
The Boston-based company said it had a loss of 48 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...
-ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year-. BOSTON, May 09, 2017-- Zafgen, Inc., today ...
Zafgen is disclosing Thursday evening the first human data on ZGN-1061, with plans to move the obesity drug into a phase II study.